U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562152) titled 'Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma' on April 20.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Pancreatic Cancer Metastatic
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Pancreatic Adenocarcinoma Metastatic
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Adenocarcinoma
Intervention:
DRUG: Atebimetinib
Once daily oral tablets
DRUG: GnP
S...